AzTrials
AzTrials

OsteoarthritisPhase 2NCT01321281

A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

A Phase 2 study testing AquaCal and AquaPT in people with Osteoarthritis, run by Andrea Doolan at 1 site in Ireland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. Read more about this study

Who is it for?
Ages 18 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Osteoarthritis
What is being tested?
AquaCal and AquaPT
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteIreland
Study dates
Mar 2011to May 2012
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • To be considered eligible for enrollment into the study, subjects must;
  • Be able to give written informed consent.
  • Be female and between 18 and 65 years of age.
  • Be a non-pregnant female.
  • Be in generally good health as determined by the investigator.
  • Osteoarthritis patients must have a clinical diagnosis of moderate to severe osteoarthritis.

Who cannot join

  • Subjects will be excluded from the study if they meet any of the below criteria;
  • Are less than 18 and greater than 65 years of age.
  • Are pregnant females.
  • Are currently taking probiotics or vitamin supplements, or have taken them in the past 14 days.
  • Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgment, entry to the study).
  • Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include non-steroidal anti-inflammatory drugs (NSAIDs), steroids and vitamin.
Show all 10Show fewer
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Subjects may not be receiving treatment involving experimental drugs.
  • If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.

Trial locations and contacts

1 site in 1 country.

Ireland1 site
  • Cork University Hospital

    Cork

Other trials in Ireland

About this study

Official title: Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.

This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.

Read the detailed description

Aquamin is a seaweed-derived mineral source, which is rich in calcium, magnesium and 74 other trace minerals including zinc, iron and selenium. It is produced from the red algae, Lithothamnion Calcareum, which is found in just three locations in the world, including the south-west coast of Ireland and Iceland. During a five-year life span, these algae absorb essential minerals from the sea - this gives Aquamin its unique multimineral content. The algae then break down naturally and settle on the sea bed. These calcified skeletal remains are harvested, washed, dried and milled and provided in a capsule formulation. AquaCal is the capsule form of Aquamin. AquaPT contains green tea and pine bark extract.

Osteoarthritis (OA) is the most common kind of arthritis. OA is called degenerative arthritis, is a disease that results from the breakdown of cartilage in joints, leading to joint pain and damage. OA is very variable and there are lots of different types affecting different joints. This degenerative disease primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. In OA, the disease begins with the degeneration of the cushion of cartilage between the joints. As it degrades, the synovium and the ends of the bones thicken, resulting in the pain and stiffness associated with arthritis. The progressive cartilage deterioration is followed by "hardening of the joints" due to calcification and bone spur formation. Treatment generally involves a combination of exercise, lifestyle modification and analgesics. If pain becomes debilitating joint replacement surgery may be used to improve the quality of life.

Symptoms of Osteoarthritis include early morning joint stiffness and pain, loss or restriction of joint mobility, pain that is worse after use, stiffness after periods of rest, creaking/cracking of joints after movement (also known as crepitus), tenderness and swelling in certain areas, restricted mobility, pain in the joint before or during changes in the weather and deformity of the joints.

Osteoarthritis is the leading cause of chronic disability in the United States.[1] It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45. A number of studies have shown that there is a greater prevalence of the disease between siblings and especially identical twins, indicating a hereditary basis [2]. Up to 60% of OA cases are thought to result from genetic factors. Other factors causing OA are congenital disorders of joints, diabetes, inflammatory diseases and all chronic forms of arthritis. In addition, injury to joints as a result of an accident, septic arthritis, Marfan syndrome, obesity, ligamentous deterioration or instability may also be factors.

Current anti-inflammatory treatments for OA while providing some relief from symptoms are suboptimal and the side effects associated with these treatments; in particular the COX-2 specific NSAID's are becoming increasingly recognized [3,4]. As a result of this, use of alternative treatments and complementary medicines are gaining popularity among OA sufferers.

In a previous study, where osteoarthritis subjects were treated with Aquamin, there was a significant improvement in the WOMAC scores for pain, stiffness, activity and composite scores over the course of the 12-week treatment, in comparison to subjects in the Placebo group[5].

Aquamin is composed of multiple minerals and the 'active ingredient' for the complex is difficult to determine. A number of the minerals in Aquamin may have anti-inflammatory and anti-oxidant properties which might directly and/or indirectly influence the efficacy of this unique complex [7,8,9]. While the prominent mineral present in Aquamin is calcium (dosage = 80% Ca U.S RDA), its role in joint health is unclear. Magnesium however, was given at the daily dosage providing 14% (male) to 18% (female) U.S. RDA [6] and over the course of this study, this increased consumption of magnesium may have influenced OA symptoms by affecting the utilization of calcium or by potentially reducing inflammation around the affected joint. Both manganese and selenium were given at the daily dosage providing up to 16% and 4% of their RDA respectfully. Both of these trace minerals have been reported to reduce the appearance of osteoarthritic lesions and reduce the severity of symptoms in OA [8,9].

Conditions
Osteoarthritis
Being tested
AquaCal, AquaPT
Keywords
Osteoarthritis
Medical subject headings
Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AquaCalDietary supplement

    AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

    The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).

  • AquaPTDietary supplement

    AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.

    The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.

Study groups in NCT01321281
Study groupRoleWhat they receive
AquaCalExperimentalOsteoarthritis and healthy volunteers
Receives: Dietary Supplement: AquaCal
AquaPTActive comparatorOsteoarthritis
Receives: Dietary Supplement: AquaPT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cytokines

    Plasma cytokine concentrations (including TNFα, IL-β, NFκB, COX2 \& IL-6)

    Measured: Baseline (wk 0) & wk 6

Secondary outcomes (3)
  1. WOMAC Questionnaire

    Western Ontario and McMaster Universities Arthritis Index

    Measured: Wk0 & Wk6

  2. Full Blood Count

    Haemaglobin, white cell count, platelet count, haematocrit, differential white count

    Measured: Wk0 & Wk6

  3. Chemistry Profile

    Including Sodium, Potassium, Chloride, Urea, Creatinine, Protein, Albumin

    Measured: Wk0 & Wk6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2011 (estimated)
  2. Study startMar 2011
  3. Primary completionMay 2012
  4. Study completionMay 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
36 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01321281
Sponsor's protocol ID
APC026-Marigot
Status last verified
May 2012
First submitted
22 Mar 2011
Last updated
15 May 2012
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AquaCal and AquaPT in people with Osteoarthritis, run by Andrea Doolan at 1 site in Ireland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cytokines (time frame: Baseline (wk 0) & wk 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in